Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.98 USD | +2.76% |
|
-5.70% | -63.39% |
05-28 | RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier | MT |
05-24 | Top Midday Decliners | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.39% | 75.47M | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- VSTM Stock
- News Verastem, Inc.
- Verastem Partners With GenFleet Therapeutics to Advance Oncology Discovery Programs